Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.

about

Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.

Item

http://www.wikidata.org/entity/Q49627919

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.

@en

Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.

@nl

type

Item

label

Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.

@en

Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.

@nl

prefLabel

Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.

@en

Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.

@nl

P1476

Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.

@en

P2093

Milind Javle

http://www.w3.org/2001/XMLSchema#string

Yun Shin Chun

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 4.0 License

P2860

Molecular profiling of biliary tract cancer: a target rich disease

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study

Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas

Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.

The metabolomic window into hepatobiliary disease.

Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.

Second-line systemic treatment for advanced cholangiocarcinoma

Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.

P304

1073274817729241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1177/1073274817729241

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28975832

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma

P932

5937242

http://www.w3.org/2001/XMLSchema#string